All In Biotech

Investigational drug · Phase 3

Pirarubicin Hydrochloride

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NMIBC.

Phase 3

Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

46

Any phase or sponsor naming "Pirarubicin Hydrochloride"

First trial start

2026

Jul 13, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Pirarubicin Hydrochloride", any sponsor or status.

Conditions studied

As listed on its trial records.

  • NMIBC

Largest trials

Live from ClinicalTrials.gov: studies naming "Pirarubicin Hydrochloride" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 21 on PubMed

Also in development for NMIBC

  • BCGPhase 38 trials

    ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis

  • SHR-1501Phase 34 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Papillary-Only Non-muscle-invasive Bladder Cancer, Patients With Advanced or Metastatic Malignant Tumors, NMIBC

  • SPGL008Phase 22 trials

    Shenyang Sunshine Pharmaceutical Co., LTD. · NMIBC, Non Small Cell Lung Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.